Also, a prospective trial correlating EPCs for NV-ARMD patients undergoing anti-VEGF pharmacotherapy may serve as a surrogate biomarker for NV-ARMD activity, and guide treatment strategies and alleviate intravitreal injection burden. Here, VEGFA is linked to age-related macular degeneration.